Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 145,445 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorder Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: exenatide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 60
States / cities: Birmingham, Alabama • Anaheim, California • Bellflower, California + 57 more

Conditions: Breast Cancer
Interventions: oophorectomy, Tamoxifen; Procedure · Drug
Lead sponsor: International Breast Cancer Research Foundation; Other
Eligibility: 18 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide (GSK716155); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 30
States / cities: Dothan, Alabama • Long Beach, California • Riverside, California + 25 more

Conditions: Osteoarthritis
Interventions: GUIDED IMAGERY, PLACEBO; Behavioral
Lead sponsor: Kent State University; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 3
States / cities: San Francisco, California • Indianapolis, Indiana

Conditions: Risk Behavior, Alcohol Use Disorder, HIV Infections
Interventions: Smartphone Based Alcohol Monitoring (SAM), Tracking and Reducing Alcohol Consumption (TRAC), TRAC-ER; Behavioral
Lead sponsor: University of Kentucky; Other
Eligibility: 18 Years to 35 Years
Enrollment: 405 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • Lexington, Kentucky

Conditions: Renal Insufficiency, Chronic Hypertension
Interventions: Spironolactone, Chlorthalidone, Placebo; Drug
Lead sponsor: Indiana Institute for Medical Research; Other
Eligibility: 19 Years to 110 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 2 Diabetes
Interventions: LY900014, Insulin Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 30
States / cities: Concord, California • Escondido, California • Fresno, California + 25 more

Conditions: Gastroparesis
Interventions: Transcutaneous Electroacupuncture, Sham TEA; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cognitive Impairment
Interventions: cognitive testing; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 55 Years to 75 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions: Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid; Drug
Lead sponsor: Joseph J. Cullen, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Tazemetostat; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 33
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Derby, Connecticut + 28 more

Conditions: Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor, Chordoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Hepatocellular Carcinoma, Classical Hodgkin Lymphoma, Colorectal Cancer, MTOR Activating Mutation
Interventions: Nab-Rapamycin, Nivolumab; Drug · Biological
Lead sponsor: Sarcoma Oncology Research Center, LLC; Other
Eligibility: 12 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Advanced Malignant Solid Neoplasm, Ovarian Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma
Interventions: Mivavotinib, Paclitaxel, Pharmacokinetic Study; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infection
Interventions: GW873140; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 34
States / cities: Tucson, Arizona • Laguna Beach, California • Long Beach, California + 30 more

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis
Interventions: PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate; Drug
Lead sponsor: Vifor Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Leukemia
Interventions: cytarabine, imatinib mesylate; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • Portland, Oregon

Conditions: Aging, Cognitive Aging, Cognitive Impairment, Cognitive Training, Mild Cognitive Impairment, Cognitively Normal Older Adults
Interventions: Piano Improvisation, Music Listening; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years and older
Enrollment: 238 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lewy Body Disease
Interventions: Galantamine; Drug
Lead sponsor: Neurological Research Center; Industry
Eligibility: 51 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 5
States / cities: Indianapolis, Indiana • Buffalo, New York • Pittsburgh, Pennsylvania + 2 more

Conditions: Chest Pain
Interventions: Aspirin, Lisinopril, Simvastatin, Lovaza, Therapeutic Lifestyle Changes; Drug · Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years to 90 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions: PLX-PAD; Biological
Lead sponsor: Pluristem Ltd.; Industry
Eligibility: 40 Years to 81 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Birmingham, Alabama • Durham, North Carolina

Conditions: Alzheimer's Disease
Interventions: ABT-089; Drug
Lead sponsor: Abbott; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 22
States / cities: Phoenix, Arizona • Sun City, Arizona • Fresno, California + 19 more

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Pancreatic Adenocarcinoma
Interventions: Prehabilitation; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 333,664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer

Pharmacokinetics/Pharmacodynamics of Albiglutide

Guided Imagery Response in Total Knee Replacement

Effects of Storage on Lactate in Blood Samples

TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

Spironolactone in CKD Enabled by Chlorthalidone: PILOT

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Transcutaneous Electroacupuncture for Gastrointestinal Motility Disorders

Pilot Testing a New Computer-based Screening Tool to Detect Cognitive Impairment

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients

Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Music Improvisation Training on Cognitive Function in Older Adults

Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies

Women With Chest Pain and Normal Coronary Arteries Study

Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

Anticoagulant Utilization Pattern